Last reviewed · How we verify
Micronized dHACM
Micronized dehydrated human amnion/chorion membrane (dHACM) provides a biologic scaffold that promotes tissue regeneration and wound healing through growth factors and extracellular matrix components.
Micronized dehydrated human amnion/chorion membrane (dHACM) provides a biologic scaffold that promotes tissue regeneration and wound healing through growth factors and extracellular matrix components. Used for Diabetic foot ulcers, Chronic wounds, Surgical wounds.
At a glance
| Generic name | Micronized dHACM |
|---|---|
| Also known as | dHACM |
| Sponsor | MiMedx Group, Inc. |
| Drug class | Biologic tissue graft / Regenerative medicine product |
| Modality | Biologic |
| Therapeutic area | Wound Care / Regenerative Medicine |
| Phase | Phase 3 |
Mechanism of action
dHACM is a decellularized human placental tissue product that contains native growth factors, cytokines, and extracellular matrix proteins. When micronized and applied to wounds or tissue defects, it acts as a biologic dressing and regenerative scaffold, promoting angiogenesis, epithelialization, and tissue remodeling while providing anti-inflammatory and antimicrobial properties.
Approved indications
- Diabetic foot ulcers
- Chronic wounds
- Surgical wounds
Common side effects
- Infection
- Allergic reaction
- Wound drainage
Key clinical trials
- Phase 2B Micronized DHACM vs. Saline in the Treatment of Knee Osteoarthritis (PHASE2)
- Micronized dHACM vs. Saline in the Treatment of Osteoarthritis of the Knee (PHASE2)
- Micronized dHACM Injectable for the Treatment of Plantar Fasciitis (PHASE3)
- Micronized dHACM Injectable for the Treatment of Achille Tendonitis (PHASE3)
- Micronized dHACM Injectable for the Treatment of Plantar Fasciitis (PHASE2, PHASE3)
- Micronized Dehydrated Human Amniotic Membrane Suspension in the Treatment of Lateral Epicondylitis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Micronized dHACM CI brief — competitive landscape report
- Micronized dHACM updates RSS · CI watch RSS
- MiMedx Group, Inc. portfolio CI